PneumRx Inc., a medical technology company, is the innovations and improvements in the treatment of lung diseases is dedicated, has expanded its intellectual property portfolio through the acquisition of key patents and domain names of Broncus Technologies.

This acquisition has now PneumRx numerous domain names, including emphysema.com, as well as several fundamental patents in the area of emphysema / interventional pulmonology.

The newly-acquired intellectual property is a valuable addition to an extensive inventory PneumRxs intellectual property rights. It allows the company to strengthen its position in relation to intellectual property rights to block competing technologies and to occupy new market segments in lung diseases.

“We are very pleased with the acquisition of intellectual property rights of Broncus, supporting the leadership of PneumRx in interventional pulmonology further,” said Erin McGurk, PneumRxs president and CEO. “PneumRx looking forward to the newly-acquired intellectual property in our task to use to provide solutions for millions of people who suffer from lung diseases.”

PneumRx is currently manufacturing the RePneu LVRC System, a minimally invasive device that is intended to improve lung function in emphysema patients by bronchoscopy Nitinol coils are implanted into the lungs to compress diseased tissue (lung volume reduction), elastic recoil adapt and restore lung compliance. This treatment offers a minimally invasive alternative to surgery for lung volume reduction with a broad spectrum of emphysema patients.

In the United States, the system RePneu LVRC the IDE approval for a clinical study has received approval in 30 locations. The device is available on the market in Europe, where it received in 2010, the CE marking.

PneumRx, Inc. is focused on developing and commercializing innovative products for the treatment of emphysema using minimally invasive techniques.